These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 16714061

  • 21. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
    Lin YL, Kung MF.
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
    [Abstract] [Full Text] [Related]

  • 22. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.
    Pugsley MK, Hancox JC, Curtis MJ.
    Pharmacol Ther; 2008 Aug; 119(2):115-7. PubMed ID: 18590766
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Double pharmacological challenge on repolarization opens new avenues for drug safety research.
    Thomsen MB.
    Br J Pharmacol; 2007 Aug; 151(7):909-11. PubMed ID: 17549050
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Preclinical cardio-safety assessment of torsadogenic risk and alternative methods to animal experimentation: the inseparable twins.
    Dumotier BM, Georgieva AV.
    Cell Biol Toxicol; 2007 Jul; 23(4):293-302. PubMed ID: 17216548
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans.
    Aubert M, Osterwalder R, Wagner B, Parrilla I, Cavero I, Doessegger L, Ertel EA.
    Drug Saf; 2006 Jul; 29(3):237-54. PubMed ID: 16524323
    [Abstract] [Full Text] [Related]

  • 29. Characterization of a non-human primate model of drug-induced torsades de pointes.
    Beatch GN, Davis DR, Dickenson DR, Adaikan PG, Hayes E, Rhamberg M, Walker MJ.
    Proc West Pharmacol Soc; 1997 Jul; 40():13-6. PubMed ID: 9436200
    [No Abstract] [Full Text] [Related]

  • 30. [Iatrogenic torsades de pointes].
    Hennemann A.
    Med Monatsschr Pharm; 2001 Aug; 24(8):262-5. PubMed ID: 11515200
    [No Abstract] [Full Text] [Related]

  • 31. Clinical study of amiodarone-associated torsade de pointes in Chinese people.
    Geng DF, Jin DM, Wang JF, Luo YJ, Wu W.
    Pacing Clin Electrophysiol; 2006 Jul; 29(7):712-8. PubMed ID: 16884506
    [Abstract] [Full Text] [Related]

  • 32. [Drug-induced arrhythmia a difficult to catch adverse effect. New guidelines for increased cardiovascular safety].
    Darpö B.
    Lakartidningen; 2006 Jul; 103(14):1094-5. PubMed ID: 16681092
    [No Abstract] [Full Text] [Related]

  • 33. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
    Aström-Lilja C, Odeberg JM, Ekman E, Hägg S.
    Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):587-92. PubMed ID: 18449951
    [Abstract] [Full Text] [Related]

  • 34. Proarrhythmic potential of antimicrobial agents.
    Simkó J, Csilek A, Karászi J, Lorincz I.
    Infection; 2008 Jun; 36(3):194-206. PubMed ID: 18454341
    [Abstract] [Full Text] [Related]

  • 35. Sensitivity and Specificity of the In Vitro Guinea Pig Papillary Muscle Action Potential Duration for the Assessment of Drug-Induced Torsades De Pointes Liability in Humans.
    Ducroq J.
    Handb Exp Pharmacol; 2015 Jun; 229():205-19. PubMed ID: 26091641
    [Abstract] [Full Text] [Related]

  • 36. Beat-to-beat variability of repolarization: a new parameter to determine arrhythmic risk of an individual or identify proarrhythmic drugs.
    Oosterhoff P, Oros A, Vos MA.
    Anadolu Kardiyol Derg; 2007 Jul; 7 Suppl 1():73-8. PubMed ID: 17584687
    [Abstract] [Full Text] [Related]

  • 37. Torsade-de-pointes in a patient under flecainide treatment, an unusual case of proarrhythmicity.
    Nogales Asensio JM, Moreno Sánchez N, Doncel Vecino LJ, Villar Mariscal C, López-Mínguez JR, Merchán Herrera A.
    Int J Cardiol; 2007 Jan 08; 114(2):E65-7. PubMed ID: 17056139
    [Abstract] [Full Text] [Related]

  • 38. Am I or am I not proarrhythmic? Comparison of various classifications of drug TdP propensity.
    Wiśniowska B, Polak S.
    Drug Discov Today; 2017 Jan 08; 22(1):10-16. PubMed ID: 27717849
    [Abstract] [Full Text] [Related]

  • 39. In silico risk assessment for drug-induction of cardiac arrhythmia.
    Suzuki S, Murakami S, Tsujimae K, Findlay I, Kurachi Y.
    Prog Biophys Mol Biol; 2008 Sep 08; 98(1):52-60. PubMed ID: 18635251
    [Abstract] [Full Text] [Related]

  • 40. [Arrhythmogenic effects of non cardiovascular drugs].
    Davy JM, Raczka F, Beck L, Cung TT, Piot C, Weissenburger J.
    Arch Mal Coeur Vaiss; 2003 Dec 08; 96 Spec No 7():37-45. PubMed ID: 15272520
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.